Halozyme Therapeutics HALO Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue from Contract with Customer, Excluding Assessed Tax by Product | |||||
| Bulk rHuPH20 sales | $133.02M+54.1% | $86.34M-25.2% | $115.44M+40.6% | $82.08M+1.4% | |
| Device licensing and development revenue | $16.86M+48.6% | $11.34M+19.0% | $9.53M-0.8% | $9.61M— | |
| Device partnered product sales | $48.81M-3.4% | $50.54M-7.4% | $54.58M+51.2% | $36.1M— | |
| Proprietary product sales | $194.61M+16.8% | $166.62M+27.4% | $130.83M+79.6% | $72.85M+213% | |
| Royalties | $867.84M+52.0% | $570.99M+27.5% | $447.87M+24.2% | $360.48M+76.8% | |
| Sales-based milestones | $70M+133% | $30M— | $0-100% | $10M— | |
| Upfront license and target nomination fees | $18.47M-31.6% | $27M+1,250% | $2M-93.3% | $30M-28.6% | |
| Accounts receivable, net and contract assets by Product | |||||
| Device partnered product sales | $192.06M+46.8% | $130.86M— | —— | —— | |
| Royalties | $878.98M+57.5% | $557.93M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Halozyme Therapeutics break its business down?
- Halozyme Therapeutics (HALO) reports revenue from contract with customer, excluding assessed tax by product across 7 parts — Bulk rHuPH20 sales, Device licensing and development revenue, Device partnered product sales, Proprietary product sales and Royalties. Each is extracted from the segment footnotes and tracked over time.
- Where does Halozyme Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Halozyme Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
